Congress Demands Answers on Data Privacy Ahead of 23andMe Sale

As news of the potential sale of genetic testing company 23andMe circulates, Congress is calling for answers regarding data privacy concerns.

Lawmakers are worried about how the sensitive genetic information of millions of users will be handled in the event of a sale.

There are fears that private health data could be misused or shared with third parties without consent.

Congress is demanding transparency from 23andMe and any potential buyers about their data privacy policies and protections.

Many are calling for stricter regulations on companies that collect and store sensitive personal information.

The sale of 23andMe could have far-reaching implications for the future of data privacy and consumer protections.

Experts warn that genetic data is particularly sensitive and should be handled with the utmost care.

Consumers are urged to carefully consider the implications of sharing their genetic information with companies like 23andMe.

Congress plans to hold hearings on the matter in the coming weeks to further investigate the potential risks and safeguards.

It is clear that the issue of data privacy in the digital age is a complex and pressing concern that requires careful consideration and oversight.